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expressed in endothelial cells (Blackburn 
and Brinckerhoff, 2008). It appears 
that MMP-1 can act directly on endo-
thelial cells as a proangiogenic signaling 
molecule to complement the effect of 
thrombin in promoting angiogenesis and 
tumor progression. Interestingly, it has 
also been shown in a breast cancer model 
that stromal fibroblast-derived MMP-1 in 
the tumor microenvironment can alter 
the behavior of tumor cells through PAR1 
by promoting cell migration and invasion 
(Boire et al., 2005). These results comple-
ment previous findings that expression of 
MMP-1 serves as a marker for rapid pro-
gression in human metastatic melanoma 
(Nikkola et al., 2002, 2005).
Since the initial identification of 
collagenase in tadpoles by Gross and 
Lapière (1962), it has become evident 
that the role of collagenases is more 
complex than that of simply promoting 
turnover of collagenous ECM. MMPs 
can proteolytically activate and release 
biologically active fragments from ECM, 
and they can also process several non-
matrix substrates embedded in the ECM 
or on the cell surface. The results of 
Zigrino et al. provide direct evidence 
that host-derived collagenases play an 
important role in tumor progression 
and that novel inhibition strategies for 
stromal collagenases may be an impor-
tant approach for targeting vasculariza-
tion of invasive malignant tumors.
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Cancer Risk Evaluation in Psoriasis:  
In Search of the Holy Grail?
Carle F. Paul1,2 and Pierre-Antoine Gourraud3
Benefit–risk assessment of systemic treatment in psoriasis is a dynamic process. 
Long-term safety of psoriasis therapies has been questioned, with the spectrum of 
systemic immunosuppression potentially leading to increased cancer risk. In this 
issue, Brauchli et al. report on a population-based analysis of cancer risk in a large 
cohort of psoriasis patients, most of whom had not been treated with systemic 
agents. The study prepares the ground for future prospective long-term cohort stud-
ies in psoriasis patients treated with systemic therapies, including biological agents.
Journal of Investigative Dermatology (2009) 129, 2547–2549. doi:10.1038/jid.2009.203
The association between psoriasis and 
cancer risk has received considerable 
attention, as has the role of certain thera-
peutic agents used to treat psoriasis in 
promoting cancer risk. Prospective cohort 
studies have demonstrated that the risk 
of nonmelanoma skin cancer increases 
linearly with the number of psoralen 
plus ultraviolet light A (PUVA) sessions 
in patients with psoriasis (Nijsten and 
Stern, 2003). In addition, treatment with 
systemic immunosuppressant agents in 
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patients previously exposed to PUVA 
has been shown to increase the risk of 
skin cancer by a factor of 2 to 3, and 
increased durations of exposure were 
found to have adverse effects as well 
(Paul et al., 2003). In contrast, the asso-
ciation between psoriasis and cancer in 
other organs remains uncertain. Some 
studies have demonstrated an increased 
risk of lymphoma in patients with psoria-
sis (Gelfand et al., 2003), but others have 
failed to show that association (Stern 
and Vakeva, 1997). Population-based 
studies from Scandinavia have suggested 
an increased risk of cancer of the respi-
ratory tract, liver, and pancreas in pso-
riasis (Boffetta et al., 2001). However, 
lifestyle factors associated with psoriasis 
(e.g., diet, tobacco smoking, and alcohol 
intake) may have acted as confounders 
in these and other studies because they 
were most often not accounted for in the 
analyses.
In this issue, Brauchli and colleagues 
report a population-based analysis 
investigating the risk of cancer in pso-
riasis patients from an automated data-
base. They found a modest association 
between psoriasis and risk of pancreatic 
cancer and risk of lymphoma (incidence 
rate ratio (IRR) = 1.81 (1.31–2.42) and 
IRR = 2.20 (1.18–4.09), respectively). 
The authors attempt to account for sev-
eral confounding factors in their analy-
sis, and the paper provides important 
information about the background risk 
of cancer in patients who were predomi-
nantly not treated with systemic agents. 
The study nicely prepares the ground for 
future prospective cohort studies.
Epidemiological studies evaluating 
the risk of cancer in psoriasis patients 
based on information obtained from 
automated databases carry several limi-
tations. First, the accuracy of diagnoses 
made by general practitioners is a matter 
of debate. Particularly in difficult cases, 
examination by dermatologists, laborato-
ry investigations, and skin biopsy are use-
ful in ruling out other conditions, such as 
cutaneous T-cell lymphoma (CTCL). The 
fact that all cases of CTCL in the study 
of Brauchli et al. (2009) occurred in the 
psoriasis group of patients suggests that 
misdiagnoses may have occurred. As 
reported previously, chronic inflamma-
tory diseases such as psoriasis or atopic 
dermatitis can be misdiagnosed as CTCL 
by nondermatologists for years (Arellano 
et al., 2007; Elmer and George, 1999). 
The absence of individual case valida-
tion makes the association between 
psoriasis and lymphoma less certain. A 
second limitation of such studies is the 
issue of family-wise error, defined as 
the probability of making at least one 
type I error among all the hypotheses 
when performing multiple tests. In data-
base studies, both the researcher and the 
reader have a tendency to conclude that 
there is “statistical significance” every 
time the 95% confidence interval of the 
IRR includes numbers that are greater 
or less than 1. In large epidemiological 
studies without a priori hypotheses, the 
risk of family-wise errors increases rap-
idly with the number of IRRs presented. 
In the study by Brauchli et al., more than 
90 IRRs are presented; therefore, the risk 
of family-wise error could be high. As 
in genomic research, multiple testing 
may be accounted for when analyzing 
data to facilitate accurate interpretation 
(Benjamini and Hochberg, 1995). The 
third issue concerns the assessment of 
comorbidities and the level of exposure 
to treatments, which may not have been 
accurately recorded in automated data-
bases, especially when the objectives of 
the study were not planned prospectively 
(Lewis and Brensinger, 2004).
It is essential to assess the complex 
relationship among psoriasis, comor-
bidities, cancer risk, and medications in 
a more effective fashion. Well-designed 
prospective cohort studies in patients 
with moderate to severe psoriasis are 
needed. These patients, who are exposed 
to carcinogens such as UV radiation 
and psoralens and to systemic immuno-
suppressants, including biological agents, 
represent a minority of patients in data-
base studies and account for only 2.6% 
of the psoriasis population in the study 
by Brauchli et al. (2009). Prospective 
cohort studies will become central to our 
understanding of the long-term safety of 
modern treatments. The ideal cohort will 
embody the fundamental epidemiologic 
measures of incidence rates of rare and 
potentially delayed adverse events, risk 
factors for these events, and their rela-
tionship to levels of exposure and to 
comorbidities.
In the past 40 years, few long-term 
prospective cohort studies have been 
completed in psoriasis, despite the 
existence of a relatively large number of 
clinical studies. This can be explained 
not only by the tremendous effort 
that is required to conduct effective 
cohort research, but also by the relative 
lack of financial support for pharma-
coepidemiology research over the past 
century. Following the approval of bio-
logical agents for treating psoriasis, 
many new initiatives in the United States 
and Europe now compete for funding 
and resources. Some research initia-
tives are driven by regulatory authorities 
through phase IV commitments. As an 
example, the planned postmarketing 
safety cohort studies of the five bio-
logical agents approved in the United 
States for psoriasis are to include more 
than 20,000 patients followed for 5 to 
10 years in five studies. One may doubt 
the feasibility of running these studies in 
parallel; however, if their promise holds 
true, our understanding of cancer risk 
in psoriasis will increase substantially. 
Simultaneous to these regulatory 
initiatives, independent cohort studies 
led by academic investigators have been 
initiated in several countries (Lecluse et 
al., 2008). Of these academic initiatives, 
a special mention should be given to the 
Italian PSOCARE project, which may 
well be the largest prospective cohort 
study of psoriasis ever conducted.
Retaining patients and sustaining phy-
sician participation in multiyear cohort 
studies, collecting and interpreting data, 
and minimizing bias and confounding 
represent challenges that, if overcome, 
promise to advance our understanding of 
the long-term benefits and risks of treat-
ment and thereby facilitate therapeutic 
decision making. The report by Brauchli 
et al. is a step in the right direction.
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Mast Cell Stabilizing Properties  
of Antihistamines
Francesca Levi-Schaffer1 and Ron Eliashar2
Histamine is a key mediator of allergic inflammation, primarily through com-
petitive antagonism of binding to H1 receptors. In this issue, Weller and Maurer 
report that the H1 antagonist desloratadine possesses mast cell–stabilizing 
properties when challenged in an IgE-dependent or -independent fashion. Thus, 
desloratadine provides benefits that are independent of H1 receptor binding 
and based on mast cell stabilization.
Journal of Investigative Dermatology (2009) 129, 2549-2551. doi:10.1038/jid.2009.256
Histamine
Several mediators are involved in the 
pathophysiology of allergic diseases. 
Among them, histamine is key, espe-
cially in urticaria and rhinitis. Histamine 
was first identified as a mediator of bio-
logical functions in the early 1900s, 
and new roles are still being identi-
fied. Histamine interacts with the four 
histamine receptor subtypes: H1, H2, 
H3, and H4. These G-protein-coupled 
receptors differ in their location, sec-
ond messengers, and histamine-binding 
properties. In allergy—from allergic 
rhinitis and conjunctivitis to urticaria, 
atopic dermatitis, and asthma—the typi-
cal histamine receptor has been thought 
to be H1, and the typical antihistamines 
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have been the H1 antagonists, which 
have been in clinical use for more than 
60 years. Recently, the role of the H4 
receptor in inflammatory and allergic 
diseases has attracted attention (Zampeli 
and Tiligada, 2009).
In the skin, histamine provokes ery-
thema, edema, and itching. In the nose, 
it induces itching, sneezing, edema, 
obstruction, and rhinorrhea. In the lungs, 
it is primarily a broncho constrictor. The 
symptoms of allergic inflammation (AI) 
are produced not only by histamine, but 
also by other inflammatory mediators 
that are released primarily by mast 
cells (MCs) and basophils activated by 
antigen–IgE interactions. Antihistamines 
act through the competitive antagonism/
inverse receptor agonism observed in 
histamine’s binding to H1 receptors on 
nerve endings, smooth muscle, and glan-
dular cells. However, it has long been 
speculated that they might also possess 
anti-inflammatory and MC-stabilizing 
capabilities.
the current evidence
Weller and Maurer (2009, this issue) 
questioned whether desloratadine has 
human skin MC-stabilizing properties. 
Desloratadine, the main metabolite 
of loratadine, is a rapidly active, 
once-daily, nonsedating, selective high-
affinity H1-receptor antagonist/inverse 
receptor agonist that can also interact 
with the five subtypes of muscarinic 
receptors. It has 10–20 times the in vivo 
receptor-binding affinity of loratadine 
and displays linear pharmacokinetics 
after oral administration. It is rapidly 
absorbed and metabolized in its first 
passage through the liver by cytochrome 
P450. Desloratadine has proven efficacy 
and safety in the control of AI symptoms 
attributable to both its anti-H1 proper-
ties and other anti-inflammatory effects.
To study the skin MC-stabilizing 
properties of desloratadine, the authors 
purified human skin MCs and then 
challenged them with anti-IgE antibodies 
or in an IgE-independent fashion with 
substance P or Ca-ionophore. Both 
histamine release and the expression 
of the MC-activating marker, CD107a, 
were evaluated after preincubation with 
and in the subsequent presence of deslo-
ratadine (10-8–10-4 M). Desloratadine 
inhibited both MC activation and 
